Voyager Therapeutics Inc (NASDAQ:VYGR) target price raised to $13.00, reported today by Zacks Investment Research
- Updated: October 12, 2016
Voyager Therapeutics Inc (NASDAQ:VYGR) had its target price raised to $13.00 by Zacks Investment Research in a report released 10/12/2016. The new target price indicates a possible upside of 0.13% based on the company's last stock close price.
Previously on 7/15/2016, Stifel Nicolaus reported about Voyager Therapeutics Inc (NASDAQ:VYGR) raised the target price from $0.00 to $33.00. At the time, this indicated a possible upside of 1.60%.
Yesterday Voyager Therapeutics Inc (NASDAQ:VYGR) traded -1.80% lower at $11.50. The company’s 50-day moving average is $12.86 and its 200-day moving average is $12.72. The last stock close price is down -10.18% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 23,721 shares of the stock were exchanged, down from an average trading volume of 54,589
See Chart Below
Voyager Therapeutics Inc has a 52 week low of $8.12 and a 52 week high of $30.54 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 3 firms have reported on the stock. The consensus target price is $28.00 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Voyager Therapeutics Inc (NASDAQ:VYGR)
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's product pipeline includes programs for Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson's Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's Ataxia, VY-HTT01 for Huntington's Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.